AI assistant
BioXcel Therapeutics, Inc. — Director's Dealing 2024
Apr 9, 2024
34564_dirs_2024-04-08_f7133632-820f-4a1e-aa12-66c405cf3cad.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BioXcel Therapeutics, Inc. (BTAI)
CIK: 0001720893
Period of Report: 2024-03-14
Reporting Person: Rodriguez Javier (See Remarks)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-03-14 | Common Stock | M | 521 | — | Acquired | 6434 | Direct |
| 2024-03-15 | Common Stock | M | 2250 | — | Acquired | 8684 | Direct |
| 2024-04-04 | Common Stock | S | 1012 | $2.6358 | Disposed | 7672 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-03-14 | Restricted Stock Units | $ | M | 521 | Disposed | Common Stock (521) | Direct | |
| 2024-03-15 | Restricted Stock Units | $ | M | 2250 | Disposed | Common Stock (2250) | Direct |
Footnotes
F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F2: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2023.
F3: The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $2.625 to $2.654. The Reporting Person undertakes to provide upon request the Securities and Exchange Commission staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
F4: On March 14, 2022, the Reporting Person was granted 8,337 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.
F5: On March 15, 2023, the Reporting Person was granted 9,000 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.